Impact Of Cytoterm On Vasomotor Symptoms (VMS) And Quality Of Life (Qol) Impairments In Patients Receiving Hormone Therapy (HT) And Radiotherapy (RT) For Prostate Cancer (Pca). Results Of The ESCULAPE Phase II Study.

被引:0
|
作者
Belkacemi, Y. [1 ,2 ,3 ]
Jouhaud, A. [2 ,4 ]
Ingels, A. [5 ]
Brunel, A. [6 ]
Coraggio, G. [2 ]
Joly, C. [7 ]
Hadhri, A. [10 ]
Hassani, W. [2 ]
Nourieh, M. [8 ]
Salazar, B. Vega [9 ]
de la Taille, A. [10 ]
Salomon, L. [11 ]
机构
[1] AROME Assoc Radiotherapy & Oncol Mediterranean Ar, Paris, France
[2] Henri Mondor Univ Hosp, AP HP, Dept Radiat Oncol, Creteil, France
[3] Univ Paris Est Creteil UPEC, Henri Mondor Breast Canc Ctr, INSERM, U955, Creteil, France
[4] Henri Mondor Univ Hosp, AP HP, Henri Mondor Breast Ctr, Creteil, France
[5] Henri Mondor Univ Hosp, Dept Urol, Creteil, France
[6] Stateo, Monaco, Monaco
[7] Henri Mondor Univ Hosp, Dept Med Oncol, Creteil, France
[8] Henri Mondor Univ Hosp, Dept Pathol, Creteil, France
[9] SAM Serelys Pharma, Monaco, Monaco
[10] Univ Paris Est UPEC, Henri Mondor Univ Hosp, AP HP, Dept Urol, Creteil, France
[11] Henri Mondor Hosp, Paris, France
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
4014
引用
收藏
页码:E864 / E865
页数:2
相关论文
共 12 条
  • [11] QoL from TASCO1: Health-related quality of life of trifluridine/tipiracil-bevacizumab and capecitabine-bevacizumab as first-line treatments in metastatic colorectal cancer patients not eligible for intensive chemotherapy-Results from the TASCO1 phase II study.
    Moiseyenko, Vladimir
    Saunders, Mark P.
    Wasan, Harpreet Singh
    Argiles, Guillem
    Borg, Christophe
    Creemers, Geert-Jan
    Fedyanin, Mikhail
    Glynne-Jones, Robert
    Pfeiffer, Per
    Punt, Cornelis J. A.
    Stroyakovskiy, Daniil
    Ten Tije, Albert J.
    de Wouw, Agnes W. Van
    Kanehisa, Akira
    Fougeray, Ronan
    Sabater, Javier
    Amellal, Nadia
    Van Cutsem, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [12] Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line Setting
    Decker, Thomas
    Zaiss, Matthias
    Klein, Dunja
    Hahn, Antje
    Hagen, Volker
    La Rosee, Paul
    Liersch, Ruediger
    Wolff, Thomas
    Hillebrand, Larissa E.
    Niemeier, Beate
    Lennartz, Carolin
    Chiabudini, Marco
    Bengsch, Fee
    Indorf, Martin
    Marschner, Norbert
    [J]. BREAST CARE, 2024, 19 (01) : 49 - 61